This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pacini, F. Articles by Pinchera, A. Search for Related Content PubMed PubMed Citation Articles by Pacini, F. Articles by Pinchera, A.

Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment

Department of Endocrinology and Metabolism, Section of Endocrinology, University of Pisa, 56124 Pisa, Italy

Address all correspondence and requests for reprints to: Furio Pacini, M.D., Department of Endocrinology, Via Paradisa, 2, 56124 Pisa, Italy. E-mail: . fpacini{at}endoc.med.unipi.it

Abstract

The follow-up of differentiated thyroid cancer after total thyroidectomy and thyroid ablation is commonly based on serum Tg determination and 131-iodine (¹³¹I) diagnostic whole-body scan (WBS) performed in the hypothyroid state, 6–12 months after thyroid ablation. Based on the greater sensitivity of Tg measurement, with respect to WBS, the diagnostic yield of diagnostic WBS has been questioned in patients who are off L-T₄ therapy and have undetectable Tg levels.

The aim of the present retrospective study was to evaluate the diagnostic relevance of ¹³¹I WBS performed after thyroid remnant ablation, in patients with undetectable serum Tg and off thyroid hormone therapy. The study included 315 of 662 consecutive patients (47.6%) treated in our department between 1980 and 1990, who, at the first control WBS after thyroid ablation, had undetectable serum Tg levels in the hypothyroid state. There were 54 men (17%) and 261 women (83%), with a mean age of 40.9 ± 13.1 yr (range, 12–76), followed for a mean of 12 ± 2.8 (range, 9–19) yr.

The control WBS was negative in 225 (71.4%) patients and positive for persistent areas of thyroid bed uptake, frequently of very low significance, in 90 (28.6%). No local or distant metastases were discovered.

At the last follow-up visit (1999–2000), 281 (89.2%) patients showed complete remission, with undetectable serum Tg off L-T₄ and negative WBS. Persistent thyroid bed uptake, with undetectable levels of Tg, was observed in 29 patients (9.2%) studied during L-T₄ withdrawal. Only 2 patients (0.6%) experienced local recurrence (lymph-node metastases) during their follow-up.

In conclusion, our data suggest that the presence of undetectable levels of serum Tg off L-T₄ at the time of the first control WBS after initial treatment, is highly predictive of complete and persistent remission. With the exception of detecting persistent thyroid bed uptake in a minority of cases, the control WBS has never given information that could influence the following therapeutic strategy. On this basis, we propose that the diagnostic ¹³¹I WBS may be avoided in patients with undetectable levels of Tg off L-T₄. These patients may be monitored with clinical examination, neck ultrasound, and serum Tg measurements on L-T₄.

This article has been cited by other articles:

				M. G. Castagna, L. Brilli, T. Pilli, A. Montanaro, C. Cipri, C. Fioravanti, F. Sestini, M. Capezzone, and F. Pacini Limited Value of Repeat Recombinant Human Thyrotropin (rhTSH)-Stimulated Thyroglobulin Testing in Differentiated Thyroid Carcinoma Patients with Previous Negative rhTSH-Stimulated Thyroglobulin and Undetectable Basal Serum Thyroglobulin Levels J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 76 - 81. [Abstract] [Full Text] [PDF]

				M. Schlumberger, A. Hitzel, M. E. Toubert, C. Corone, F. Troalen, M. H. Schlageter, F. Claustrat, S. Koscielny, D. Taieb, M. Toubeau, et al. Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2487 - 2495. [Abstract] [Full Text] [PDF]

				K. S. Heller Do All Cancers Need to Be Treated? The Role of Thyroglobulin in the Management of Thyroid Cancer: The 2006 Hayes Martin Lecture Arch Otolaryngol Head Neck Surg, July 1, 2007; 133(7): 639 - 643. [Full Text] [PDF]

				R. C. Smallridge, S. E. Meek, M. A. Morgan, G. S. Gates, T. P. Fox, S. Grebe, and V. Fatourechi Monitoring Thyroglobulin in a Sensitive Immunoassay Has Comparable Sensitivity to Recombinant Human TSH-Stimulated Thyroglobulin in Follow-Up of Thyroid Cancer Patients J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 82 - 87. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. W A Smit, W. Wiersinga, and the European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol., June 1, 2006; 154(6): 787 - 803. [Full Text] [PDF]

				F. Pacini, P. W. Ladenson, M. Schlumberger, A. Driedger, M. Luster, R. T. Kloos, S. Sherman, B. Haugen, C. Corone, E. Molinaro, et al. Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 926 - 932. [Abstract] [Full Text] [PDF]

				M. Torlontano, U. Crocetti, G. Augello, L. D'Aloiso, N. Bonfitto, A. Varraso, F. Dicembrino, S. Modoni, V. Frusciante, A. Di Giorgio, et al. Comparative Evaluation of Recombinant Human Thyrotropin-Stimulated Thyroglobulin Levels, 131I Whole-Body Scintigraphy, and Neck Ultrasonography in the Follow-Up of Patients with Papillary Thyroid Microcarcinoma Who Have Not Undergone Radioiodine Therapy J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 60 - 63. [Abstract] [Full Text] [PDF]

				R. T. Kloos and E. L. Mazzaferri A Single Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Measurement Predicts Differentiated Thyroid Carcinoma Metastases Three to Five Years Later J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5047 - 5057. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri Empirically Treating High Serum Thyroglobulin Levels J. Nucl. Med., July 1, 2005; 46(7): 1079 - 1088. [Full Text] [PDF]

				F. Santini, A. Pinchera, A. Marsili, G. Ceccarini, M. G. Castagna, R. Valeriano, M. Giannetti, D. Taddei, R. Centoni, G. Scartabelli, et al. Lean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 124 - 127. [Abstract] [Full Text] [PDF]

				R. J. Robbins and M. J. Schlumberger The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 28S - 37S. [Abstract] [Full Text] [PDF]

				M. Torlontano, M. Attard, U. Crocetti, S. Tumino, R. Bruno, G. Costante, G. D'Azzo, D. Meringolo, E. Ferretti, R. Sacco, et al. Follow-Up of Low Risk Patients with Papillary Thyroid Cancer: Role of Neck Ultrasonography in Detecting Lymph Node Metastases J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3402 - 3407. [Abstract] [Full Text] [PDF]

				R. Elisei, A. Vivaldi, L. Agate, E. Molinaro, C. Nencetti, L. Grasso, A. Pinchera, and F. Pacini Low Specificity of Blood Thyroglobulin Messenger Ribonucleic Acid Assay Prevents Its Use in the Follow-Up of Differentiated Thyroid Cancer Patients J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 33 - 39. [Abstract] [Full Text] [PDF]

				D. Barbaro, G. Boni, G. Meucci, U. Simi, P. Lapi, P. Orsini, C. Pasquini, F. Piazza, M. Caciagli, and G. Mariani Radioiodine Treatment with 30 mCi after Recombinant Human Thyrotropin Stimulation in Thyroid Cancer: Effectiveness for Postsurgical Remnants Ablation and Possible Role of Iodine Content in L-Thyroxine in the Outcome of Ablation J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4110 - 4115. [Abstract] [Full Text] [PDF]

				F. Pacini, E. Molinaro, M. G. Castagna, L. Agate, R. Elisei, C. Ceccarelli, F. Lippi, D. Taddei, L. Grasso, and A. Pinchera Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Combined with Neck Ultrasonography Has the Highest Sensitivity in Monitoring Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3668 - 3673. [Abstract] [Full Text] [PDF]

				R. J. Robbins and K. S. Pentlow Coming of Age: Recombinant Human Thyroid-Stimulating Hormone as a Preparation for 131I Therapy in Thyroid Cancer J. Nucl. Med., July 1, 2003; 44(7): 1069 - 1071. [Full Text] [PDF]

				E. L. Mazzaferri, R. J. Robbins, C. A. Spencer, L. E. Braverman, F. Pacini, L. Wartofsky, B. R. Haugen, S. I. Sherman, D. S. Cooper, G. D. Braunstein, et al. A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1433 - 1441. [Abstract] [Full Text] [PDF]

				E. Baudin, C. D. Cao, A. F. Cailleux, S. Leboulleux, J. P. Travagli, and M. Schlumberger Positive Predictive Value of Serum Thyroglobulin Levels, Measured during the First Year of Follow-Up after Thyroid Hormone Withdrawal, in Thyroid Cancer Patients J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1107 - 1111. [Abstract] [Full Text] [PDF]

				S. I. Sherman Optimizing the Outcomes of Adjuvant Radioiodine Therapy in Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4059 - 4062. [Full Text] [PDF]

				L. Wartofsky Using Baseline and Recombinant Human TSH-Stimulated Tg Measurements to Manage Thyroid Cancer without Diagnostic 131I Scanning J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1486 - 1489. [Full Text] [PDF]